TherapeuticsMD, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)

	Years ended December 31,
	2025	2024
Cash flows from operating activities:
Net loss	$(569)	$(2,181)
Less: Income from discontinued operations, net of tax	84	131
Net loss from continuing operations	(653)	(2,312)
Adjustments to reconcile net loss to net cash provided by continuing operating activities:
Depreciation and amortization	384	509
Write-off and impairment of patents	176	1,268
Share-based payment compensation costs	75	264
Amortization of right of use assets	809	771
Changes in operating assets and liabilities:
Prepaid and other current assets	201	397
Other assets	2,020	1,930
Accounts payable	119	231
Accrued expenses and other current liabilities	272	(1,006)
Lease liabilities	(1,078)	(990)
Other non-current liabilities	129	108
Total adjustments	3,107	3,482
Net cash provided by continuing operating activities	2,454	1,170
Discontinued operations:
Net cash used in operating activities	(30)	(438)
Net cash used in discontinued operations	(30)	(438)
Net increase in cash	2,424	732
Cash and cash equivalents - continuing operations, beginning of period	5,059	4,327
Total cash and cash equivalents, end of period	$7,483	$5,059

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.